Trial watch: Dendritic cell-based anticancer therapy

被引：67

作者：

Bloy, Norma ^{[1
,2
,3
,4
]}

Pol, Jonathan ^{[1
,2
,3
]}

Aranda, Fernando ^{[1
,2
,3
]}

Eggermont, Alexander ^{[1
]}

Cremer, Isabelle ^{[2
]}

Fridman, Wolf Herve ^{[2
,5
,6
]}

Fucikova, Jitka ^{[7
,8
,9
]}

Galon, Jerome ^{[2
,6
,10
,11
]}

Tartour, Eric ^{[11
,12
,13
]}

Spisek, Radek ^{[7
,8
,9
]}

Dhodapkar, Madhav V. ^{[14
]}

Zitvogel, Laurence ^{[15
]}

Kroemer, Guido ^{[2
,3
,11
,13
,16
,17
]}

Galluzzi, Lorenzo ^{[1
,2
,3
,11
]}

机构：

[1] Gustave Roussy Canc Campus, Villejuif, France

[2] INSERM, U1138, Paris, France

[3] Ctr Rech Cordeliers, Equipe Labellisee Ligue Natl Canc 11, Paris, France

[4] Univ Paris 11, Orsay, France

[5] Ctr Rech Cordeliers, Equipe 13, Paris, France

[6] Univ Paris 06, Paris, France

[7] Charles Univ Prague, Sch Med 2, Dept Immunol, Prague, Czech Republic

[8] Univ Hosp Motol, Prague, Czech Republic

[9] Sotio As, Prague, Czech Republic

[10] Ctr Rech Cordeliers, Lab Integrat Canc Immunol, Paris, France

[11] Univ Paris 05, Sorbonne Paris Cite, Paris, France

[12] INSERM, U970, Paris, France

[13] Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France

[14] Yale Univ, Dept Med Immunobiol, New Haven, CT USA

[15] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[16] INSERM, U1015, CICBT507, Villejuif, France

[17] Gustave Roussy Canc Campus, Metabol & Cell Biol Platforms, Villejuif, France

来源：

ONCOIMMUNOLOGY | 2014年 / 3卷 / 11期

基金：

欧洲研究理事会;

关键词：

antigen cross-presentation; autophagy; DC-based vaccination; immunogenic cell death; regulatory T cells; Toll-like receptor agonists; INDUCED KILLER-CELLS; INDUCE ANTITUMOR IMMUNITY; ANTIGEN-PRESENTING CELLS; CYTOTOXIC T-LYMPHOCYTES; APOPTOTIC TUMOR-CELLS; IN-VIVO; CANCER-IMMUNOTHERAPY; MESSENGER-RNA; DC-SIGN; BREAST-CANCER;

D O I：

10.4161/21624011.2014.963424

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The use of patient-derived dendritic cells (DCs) as a means to elicit therapeutically relevant immune responses in cancer patients has been extensively investigated throughout the past decade. In this context, DCs are generally expanded, exposed to autologous tumor cell lysates or loaded with specific tumor-associated antigens (TAAs), and then reintroduced into patients, often in combination with one or more immunostimulatory agents. As an alternative, TAAs are targeted to DCs in vivo by means of monoclonal antibodies, carbohydrate moieties or viral vectors specific for DC receptors. All these approaches have been shown to (re) activate tumor-specific immune responses in mice, often mediating robust therapeutic effects. In 2010, the first DC-based preparation (sipuleucel-T, also known as Provenge((R))) has been approved by the US Food and Drug Administration (FDA) for use in humans. Reflecting the central position occupied by DCs in the regulation of immunological tolerance and adaptive immunity, the interest in harnessing them for the development of novel immunotherapeutic anticancer regimens remains high. Here, we summarize recent advances in the preclinical and clinical development of DC-based anticancer therapeutics.

引用

页码：e963424 / 1

页数：16

共 353 条

[1]

Abediankenari Saeid, 2013, Acta Med Iran, V51, P284

[2] B subunit of Shiga toxin-based Vaccines synergize with α-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity [J].